TPC
DNLI icon

Takeda Pharmaceutical Company’s Denali Therapeutics DNLI Stock Holding History

Takeda Pharmaceutical Company’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,214,559
Closed -$97.9M – 11
2024
Q2 		$97.9M Hold
4,214,559
– – 42.13% 1
2024
Q1 		$86.5M Hold
4,214,559
– – 29.92% 2
2023
Q4 		$86.9M Buy
+4,214,559
New +$83.5M 26.55% 2

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Takeda Pharmaceutical Company's DNLI Position: Q3 2024 in Review

Takeda Pharmaceutical Company sold out of Denali Therapeutics (DNLI) in Q3 2024, closing a stake of 4,214,559 shares — an estimated $97.9M sold.

Takeda Pharmaceutical Company first reported a position in DNLI in Q4 2023 and held it in 3 quarters. The position peaked at $97.9M in Q2 2024. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

  • Takeda Pharmaceutical Company reported no remaining Denali Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Takeda Pharmaceutical Company sold 4,214,559 Denali Therapeutics shares in Q3 2024, an estimated $97.9M.
  • Takeda Pharmaceutical Company first reported a position in Denali Therapeutics in Q4 2023 and held it in 3 quarters.
  • Takeda Pharmaceutical Company's Denali Therapeutics position peaked at $97.9M in Q2 2024.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2024, filed 13 Feb 2025.